Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nivolumab + cabozantinib or nivolumab + ipilimumab + cabozantinib versus sunitinib in previously untreated advanced or metastatic clear-cell renal cell carcinoma
MOH_2018-02-22_000715Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Nivolumab + cabozantinib, Nivolumab + ipilimumab + cabozantinib and Sunitinib (3 arms). Started Oct 2017; status: active, not recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on MOH_2018-02-22_000715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-22_000715.